Vaccination has been a game changer in our efforts to address the coronavirus disease 2019 (COVID-19) pandemic. However, the disease might still represent a clinical crisis for several more years, in part because of the inevitable emergence of variants capable of evading the preexisting immunity. Drugs affecting viral spread will help curtail transmission, but therapeutics are needed to treat the more severe cases requiring hospitalization. A deep analysis of the evolving immune landscape of COVID-19 suggests that understanding the molecular bases of the distinct clinical stages is paramount if we are to limit the burden of inflammation, which can lead to death in frail individuals, according to age, sex, and comorbidities. Different phases can be defined using immune biomarkers and need specific therapeutic approaches, tailored to the underlying immune contexture.

Ferraccioli, G., Gremese, E., Goletti, D., Petrone, L., Cantini, F., Ugel, S., Cane, S., Bronte, V., Immune-Guided Therapy of COVID-19, <<CANCER IMMUNOLOGY RESEARCH>>, 2022; 10 (4): 384-402. [doi:10.1158/2326-6066.CIR-21-0675] [http://hdl.handle.net/10807/208804]

Immune-Guided Therapy of COVID-19

Ferraccioli, G.;Gremese, E.;Goletti, D.;
2022

Abstract

Vaccination has been a game changer in our efforts to address the coronavirus disease 2019 (COVID-19) pandemic. However, the disease might still represent a clinical crisis for several more years, in part because of the inevitable emergence of variants capable of evading the preexisting immunity. Drugs affecting viral spread will help curtail transmission, but therapeutics are needed to treat the more severe cases requiring hospitalization. A deep analysis of the evolving immune landscape of COVID-19 suggests that understanding the molecular bases of the distinct clinical stages is paramount if we are to limit the burden of inflammation, which can lead to death in frail individuals, according to age, sex, and comorbidities. Different phases can be defined using immune biomarkers and need specific therapeutic approaches, tailored to the underlying immune contexture.
Inglese
Ferraccioli, G., Gremese, E., Goletti, D., Petrone, L., Cantini, F., Ugel, S., Cane, S., Bronte, V., Immune-Guided Therapy of COVID-19, <<CANCER IMMUNOLOGY RESEARCH>>, 2022; 10 (4): 384-402. [doi:10.1158/2326-6066.CIR-21-0675] [http://hdl.handle.net/10807/208804]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/208804
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 6
social impact